IP Library Granted Patent US 10,874,610
Granted Patent B2
US 10,874,610 · App. 15/788,709 · Granted Dec 29, 2020

Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer

Inventors: Huiping Liu (Chicago, IL); Erika K. Ramos (Chicago, IL); Nurmaa K. Dashzeveg (Chicago, IL); Golam Kibria (Chicago, IL)
Assignees: Northwestern University; Case Western Reserve University
A61K9/127A61K9/1277A61K31/7105C07K14/70503C07K14/70596G01N33/57415G01N33/57484G01N33/57488A61K38/00C07K2319/03C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,610
App. No.
15/788,709
Granted
Dec 29, 2020
Kind
B2
Abstract

This invention is related to use of exosomes for biomarker analysis for early detecting and characterizing of disease progression of cancer. Further, the invention provides bioengineered exosomes for use in methods of targeting and treating cancer.

Claims (15)

1. A method of bioengineering exosomes for targeting cancer cells, the method comprising:

(a) expressing a XPepα fusion protein encoded by SEQ ID NO:2 in a host cell;

(b) isolating secreted exosomes comprising the fusion protein; and

(c) loading the isolated exosomes with a least one RNA oligonucleotide or chemotherapeutic agent.

2. The method of claim 1 , wherein step (a) comprises transducing the host cell with a viral vector encoding the fusion protein.

3. A bioengineered exosome made by the method of claim 1 .

4. A therapeutic bioengineered exosome comprising a XPepα fusion protein encoded by SEQ ID NO:2.

5. The therapeutic bioengineered exosome of claim 4 further comprising at least one RNA oligonucleotide or chemotherapeutic agent.

6. The therapeutic bioengineered exosome of claim 5 , wherein the RNA oligonucleotide is a siRNA or miRNA specific for cancer.

7. The therapeutic bioengineered exosome of claim 6 , wherein the cancer is breast cancer and wherein the miRNA is miR-200, miR30c, or miR206.

8. A method of treating a patient with cancer, the method comprising administering an effective amount of the therapeutic bioengineered exosome of claim 5 to the patient with cancer.

9. The method of claim 8 , wherein the patient has a solid tumor cancer.

10. The method of claim 1 , wherein step (c) comprises loading the at least one RNA oligonucleotide or chemotherapeutic agent by electroporation of the exosomes.

11. The method of claim 1 , wherein the RNA oligonucleotide is a siRNA or miRNA specific for breast cancer.

12. The method of claim 8 , wherein the cancer is breast cancer and wherein the at least one RNA oligonucleotide is a miRNA selected from the group consisting of miR-200, miR30c, and miR206.

Assignments (3)
CONFIRMATORY LICENSE Recorded May 16, 2023
From: NORTHWESTERN UNIVERSITY
To: UNITED STATES GOVERNMENT
Reel/Frame 063649/0631 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2020
From: NORTHWESTERN UNIVERSITY
To: NORTHWESTERN UNIVERSITY; CASE WESTERN RESERVE UNIVERSITY
Reel/Frame 053498/0124 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2017
From: LIU, HUIPING; RAMOS, ERIKA; DASHZEVEG, NURMAA K; KIBRIA, GOLAM
To: NORTHWESTERN UNIVERSITY
Reel/Frame 044318/0452 →
Continuity (2)
Provisional Application 62409921 · Oct 19, 2016
Related Publication 20180104187A1 · Apr 19, 2018